Identifying populations of older adults with myeloma who receive no treatment could help mitigate disparities. Among 3800 patients with active myeloma in the SEEReMedicare database, almost 40% had no insurance claims for systemic treatment. Older age, poor performance indicators, comorbidities, African-American race, and lower socioeconomic status, including enrollment in Medicaid, were significant factors associated with receipt of no systemic treatment. Background: With the expanding armamentarium of therapeutic agents for multiple myeloma (MM), it is important to identify any undertreated patient populations to mitigate outcome disparities. Materials and Methods: We extracted the data for all plasma cell myeloma cases (International Classification of Disease for Oncology, third revision code 9732) in the Surveillance, Epidemiology, End Results (SEER)eMedicare database from 2007 to 2011. The ICD-O-3 histologic code 9732 captures both active MM and smoldering/asymptomatic myeloma. We defined active MM as either claims indicating receipt of treatments approved for MM or ICD-9 codes for MM-defining clinical features, referred to as the CRAB criteria (calcium [elevated], renal failure, anemia, bone lesions). Multivariate logistic regression was performed to determine the variables that were independently associated with receipt of no treatment. Results: Of the initial 4187 patients included in the present study, 373 had no claims indicating receipt of treatments approved for MM and had no ICD-9 codes associated with the CRAB criteria and were excluded from the analyses. Of the 3814 patients with active MM, 1445 (38%) did not have any claims confirming that they had received systemic treatment. Older age, poor performance indicators, comorbidities, African-American race, and lower socioeconomic status, including enrollment in Medicaid, were statistically significant factors associated with the receipt of no systemic treatment. Conclusions: In the present retrospective study of data from the SEEReMedicare database, we found that age, health status, race, and socioeconomic status were associated with receipt of MM treatment. These factors have previously been linked to reduced usage of specific treatments for MM, such as stem cell transplantation. To the best of our knowledge, however, ours is the first study to show their association with the receipt of any MM therapy.
Introduction
Although advances in multiple myeloma (MM) treatment have improved overall survival, disparities exist in the groups enjoying the benefit of these advances. 1 Historically, older patients have been less likely to receive treatment compared with younger patients. 2 In addition, studies have suggested inferior treatment and survival outcomes among African-American patients with MM. 3, 4 However, when treatment has been similar, the outcomes have been similar or even superior among African-American patients. [4] [5] [6] [7] [8] In addition to age and race, other barriers to treatment include limited health literacy, 9, 10 patients' financial constraints, 11 and professional education gaps resulting in delayed dissemination and implementation of advances in treatment into community practice. 12 Population-level data allow us to examine real-world practice patterns, which could reveal disparities that are not evident in clinical trials and studies of selected populations. For example, a retrospective cohort analysis of patients with a diagnosis of first primary acute myeloid leukemia in the linked Surveillance, Epidemiology, and End Results (SEER)eMedicare database from 2000 to 2009 showed that 60% of older adults in general practice had received no treatment within 3 months of the diagnosis. 13 In the National Cancer Institute Patterns of Care study, now > 10 years old, 20% to 30% of patients with MM had received no treatment with chemotherapy or novel agents within the first 12 months after the diagnosis. 14 The expanding armamentarium of therapeutic agents for MM has empowered physicians to choose appropriate treatment options, incorporating consideration of the side effect profile, financial burden, and individual patient preferences and enhancing survival outcomes. Given the availability of a broad range of therapeutic options, including monoclonal antibodies, immunomodulatory drugs (IMiDs), proteasome inhibitors, histone deacetylase inhibitors, chemotherapeutic agents, and autologous stem cell transplantation, 15 it is essential to identify the untreated and undertreated patient populations stratified by the different patient characteristics, treatment-related morbidity and mortality issues, and healthcare system impediments. In the present study, we considered primarily the effect of age on therapy and, specifically, how age and other factors predict for the receipt of no MM therapy. The identification of these factors could provide the opportunity to minimize barriers to treatment and thereby benefit a greater number of patients afflicted by MM.
Materials and Methods

Data Sources
We used a retrospective cohort analysis of the data from patients with MM in the linked SEEReMedicare database. The SEER program of the National Cancer Institute is a source of epidemiologic data on the incidence and survival rates of cancer in the United States. In the SEEReMedicare interlinked database, the SEER data registry is linked to Medicare enrollment and claims data. At the time the present study was conducted, the SEEReMedicare linked database included all Medicare-eligible persons with data in the SEER database through 2011 and their Medicare claims through 2013. The human studies committee at Washington University School of Medicine approved the present study.
Patient Selection
Eligible patients were those with a diagnosis of MM from January 1, 2007 to December 31, 2011, aged > 65 years at diagnosis, and continuously enrolled in Medicare parts A, B, and D starting the year before the diagnosis. The International Classification of Diseases for Oncology, third revision (ICD-O-3) histology code 9732 (plasma cell myeloma) captures both symptomatic MM and smoldering MM (SMM). 16 MM warrants treatment; however, SMM can be managed through a wait-and-watch strategy. We defined symptomatic MM as claims for chemotherapeutic agents effective in MM (bortezomib, cyclophosphamide, doxorubicin, lenalidomide, melphalan, thalidomide, vincristine; unspecified antineoplastic chemotherapy or immunotherapy; or autologous or allogeneic stem cell transplantation) or for ICD-9 codes for MM-defining clinical features, referred to as the CRAB criteria (calcium [elevated] , renal failure, anemia, bone lesions) within 6 months of the diagnosis, as previously described. 17 The diagnosis and procedural codes for the administration of injectable agents and the generic names of the prescription drugs approved by the US Food and Drug Administration for MM were used to differentiate patients who had and had not received treatment. Novel therapies were defined as bortezomib, lenalidomide, or thalidomide within 6 months after the diagnosis of MM. Pomalidomide, carfilzomib, vorinostat, elotuzumab, and daratumumab were not considered because they were approved after the study period. Dexamethasone or other corticosteroids were not categorized as treatment because of their broad use for a wide array of diagnoses and hence the lack of specificity for their use in determining whether a patient had received MM treatment. 17 In accordance with the current National Comprehensive Cancer Network guidelines, radiation therapy is not considered a treatment modality for frontline therapy for MM. Thus, steroids, radiation therapy, and surgery were not categorized as frontline treatment of this systemic disease.
Study Variables
We investigated the following variables to determine whether they are associated with the receipt of no treatment in patients with symptomatic MM:
Age: patient's chronologic age at the diagnosis Race: race was categorized as African-American, white, and other, including Asian and Hispanic backgrounds Socioeconomic status: the median annual household income at the census tract level of each patient's home residence at the diagnosis and enrollment in Medicaid were used as surrogates for socioeconomic status Comorbidities: we used established algorithms to calculate the Charlson comorbidity index (CCI) score for each patient using the claims for the 12 months before MM diagnosis 18, 19 Performance status indicators: SEER does not encompass objective measurements of performance status, such as the Eastern Cooperative Oncology Group or Karnofsky performance status scale; Medicare claims were used to identify factors indicating poor performance status, including, but not limited to, manual wheelchairs and power mobility devices, skilled nursing care, physical therapy and occupational therapy services, speechlanguage pathology services, and oxygen equipment and accessories used in the 12 months before the diagnosis of MM, as previously described 20 
Statistical Analysis
All statistical analyses were performed using SAS Enterprise Guide, version 5.1. The demographic and clinical characteristics were summarized by treatment status (receipt of treatment vs. receipt of no treatment). The c 2 test for categorical variables and analysis of variance test for continuous variables differentiated the differences between the 2 treatment groups. Univariate and multivariate logistic regression models were created to determine the variables that were independently associated with (1) receipt of no MM treatment overall and (2) receipt of no novel therapies. P < .05 was considered to indicate statistically significant.
Results
A total of 4187 patients were included in the primary analysis. Of these 4187 patients, 373 were considered to have a diagnosis of
Undertreatment of Older Patients With MM smoldering or asymptomatic MM owing to the lack of diagnostic codes for CRAB criteria or treatment and thus were excluded from all analyses. This left 3814 patients for the final analysis.
The median age of the cohort at the diagnosis was 76 years (range, 65-100 years). Of the 3814 patients, 1964 (51%) were female, 2923 (77%) were white, 629 were African American (16%), and 262 (7%) belonged to other races. Also, 922 patients (24%) were found to have 1 poor performance status indicator. Of the 3814 patients, 2701 (71%) had 1 comorbidity according to the CCI, and 1245 (33%) were enrolled in Medicaid in addition to Medicare. The characteristics of patient population are summarized in Table 1 .
Among the patients with symptomatic MM, 1445 (38%) did not have any claims for systemic treatment. At a median follow-up of 26 months, 70% of the study population had died. The median overall survival for the patients who had received no treatment was 9.6 months (95% confidence interval [CI], 8.0-12.0 months) versus 32.3 months (95% CI, 30.3-34.4 months) for those who had received treatment.
Older age increased the odds of not receiving treatment by 7% per year of age (adjusted odds ratio [aOR], 1.07 per year of increasing age; 95% CI, 1.06-1.08 per year of increasing age). Patients of African-American descent were 26% more likely to receive no treatment (aOR, 1.26; 95% CI, 1.03-1.54). Patients with poor performance status indicators had a 49% greater odds of receiving no treatment (aOR, 1.49; 95% CI, 1.25-1.77). Comorbidities were associated with receiving no treatment, with the odds increasing by 17% per 1 point of CCI score increase (aOR, 1.17; 95% CI, 1.12-1.21). The odds of receiving no treatment were increased by 21% for patients enrolled in Medicaid in addition to Medicare (aOR, 1.21; 95% CI, 1.02-1.42). Over time, the odds of receiving no treatment decreased; for each year increase in the year of diagnosis, the odds of receiving no treatment decreased by 10% (aOR, 0.90; 95% CI, 0.85-0.94). The median annual household income, other race, and gender were not associated with treatment receipt status on multivariate analysis. The factors associated with the receipt of no treatment are presented in Table 2 .
Of the patients who had any claim indicating receipt of treatment, the vast majority (93%) received novel therapies. A separate analysis was performed to examine the factors associated with the receipt of no novel therapies. Older patients were less likely to receive novel therapies, with the odds of receiving no novel therapies increasing by 7% per year of age (aOR, 1.07; 95% CI, 1.06-1.08). The odds of not receiving novel therapies were 52% greater for patients with poor performance status indicators (aOR, 1.52; 95% CI, 1.28-1.81). Comorbidities were associated with not receiving novel therapies, with the odds increasing by 15% per 1 point increase in the CCI score (aOR, 1.15; 95% CI, 1.10-1.19). For each year increase in the year of diagnosis, the odds of receiving no novel therapies decreased by 13% (aOR, 0.87; 95% CI, 0.83-0.91). Unlike the analysis of factors associated with the receipt of no treatment overall, African-American descent and dual MedicaideMedicare enrollment were not associated with the receipt of no novel therapies on multivariate analysis. The factors associated with receipt of no novel therapies are summarized in Table 3 .
Discussion
The results of our study have demonstrated that a significant portion of patients with MM are not receiving treatment within 6 months of their MM diagnosis. Patients who did not receive treatment with that period had significantly worse outcomes. In 2014, the International Myeloma Working Group added 3 specific biomarkers to the classic MM-defining clinical features, referred to as CRAB criteria. These 3 biomarkers included clonal bone marrow plasma cells 60%, serum free light chain ratio 100, provided the involved free light chain level was 100 mg/L, or > 1 focal lesion on magnetic resonance imaging. The revised International Myeloma Working Group diagnostic criteria for MM accentuate the necessity for an earlier diagnosis and treatment of MM to prevent organ damage and optimize the care for patients with MM. 21 In addition, we found that older age, African-American race, poor performance status indicators, comorbidities, and dual MedicaideMedicare enrollment were independently associated with not receiving treatment. Despite the significant improvement in the survival outcomes of older patients with MM within the past decade, the outcomes of older patients continue to lag behind those of young and fit patients. 22 Our study found that age was associated with the receipt of no treatment, even after controlling for comorbidities and indicators of poor performance status. Age-related undertreatment of the older population is 1 likely factor contributing to the poorer outcomes of older adults. 1 In the present era, chronologic age should not be the sole measure of aging. 23 The field of geriatric oncology is abandoning traditional patterns of using chronologic age and transitioning to a more modern paradigm of considering patients' physiologic age in approaching therapeutic decision-making in clinical practice 24 and determining eligibility for enrollment in clinical trials. 25, 26 In a study by the International Myeloma Working Group, a frailty score comprising age, functional status (measured by independence in activities of daily living and instrumental activities of daily living), and comorbidities was associated with overall survival outcomes and nonhematologic adverse events, regardless of International Staging System stage, chromosome abnormalities, and therapeutic options. 27 The frailty score was associated with a greater risk of treatment-related toxicity. These same factors of age, poor performance status indicators, and comorbidities were associated with undertreatment in our study, raising the possibility that clinicians had estimated a greater risk of toxicity for these patients, which could have potentially affected their recommendations to individual patients. Clinical trials have been specifically designed for intermediate-fit and frail patients to help instruct guidelines to personalize therapy for older patients. 28 The frailty score has the capacity to be used in future prospective trials for prognostic purposes. It also can more accurately define the overall fitness of the population, which cannot be captured by age alone. Moreover, patients with MM with a poor frailty score are still in urgent need of receiving appropriate therapies and high-quality research to determine the suitable treatment strategies for this patient population. 29 To address this unmet need, the Institute for Advanced Studies in Aging and Geriatric Medicine has called for clinical trials for frail patients with MM to improve evidence-based clinical guidelines to enhance the outcomes of older patients. 30 In our study, African-American race was associated with the receipt of no treatment overall; however, it was not a statistically significant factor for the receipt of novel therapies. In a SEER-based study by Costa et al, 1 the relative survival rates were measured among 3 major race groups (non-Hispanic whites, non-Hispanic African Americans, and Hispanics) in patients with MM since the beginning of the era of targeted therapies. The 10-year relative survival rate showed improvement in all race groups, except for nonHispanic African-American patients. These results point to a continued racial disparity affecting survival outcomes. 1 In another analysis of the SEEReMedicare database by our group, the patterns of autologous stem cell transplantation and bortezomib use among patients with MM were reviewed from 2003 to 2011. We found that African-American patients were 37% (P < .0001) less likely to undergo stem cell transplantation and 21% (P < .0001) were less likely to be treated with bortezomib. 4 These results further highlight the existing racial disparities affecting MM outcomes. Our present study, however, revealed that AfricanAmerican race was not associated with the receipt of novel therapies. An additional study by our group studying MM cases from 2007 to 2013 in the SEEReMedicare database found that AfricanAmerican race was not associated with reduced usage of lenalidomide for first-line treatment of MM. 31 Given that the data from our present study were collected from 2007 to 2011, it is possible that, in the course of time, novel agents have become more accessible to African-American patients compared with the earlier period of novel therapies.
Our results disclosed that dual MedicareeMedicaid enrollment was associated with the receipt of no treatment overall but was not associated with the receipt of no novel therapies. Another SEEReMedicare study examined the association between lowincome subsidy (LIS) receipt and the use of oral IMiDs, delays between IMiD refills, and certain outcomes among part D beneficiaries with MM. The odds of receiving IMiDs was 32% (95% CI, 16%-47%) greater for LIS recipients aged 75 to 84 years compared with LIS nonrecipients. LIS receipt significantly lowered refill delays in all age groups (adjusted relative risk, 0.54; 95% CI, 0.32-0.92). In addition, LIS recipients had fewer emergency department visits and hospital admissions compared with LIS nonrecipients. 32 These results point toward barriers to access and affordability as potential causes of the outcome disparities in patients with MM. We acknowledge that in a subset of older and frail patients, the risks of treatments approved for MM might outweigh the benefits or might not be in line with the individual's goals of care. Although the present study focused on effective frontline treatment modalities included in the National Comprehensive Cancer Network guidelines, 33 many patients whose treatment was categorized as "no treatment" in the present study might have received supportive care, including corticosteroids, bisphosphonates for hypercalcemia and skeletal lesions, radiation therapy for skeletal lesions, intravenous gamma globulin for the prevention of infections, and plasmapheresis for hyperviscosity syndrome. 34 In the present study, poor performance status indicators and comorbidities increased the odds of receiving no treatment (aOR, 1.49; 95% CI, 1.25-1.77; aOR, 1.17; 95% CI, 1.12-1.21, respectively). Such patients are more likely to opt for supportive care and, potentially, hospice enrollment, although this outcome was beyond the scope of the present 35 The distinct characteristics of MM compared with other hematologic malignancies, such as incurability and intractable pain related to bone lesions toward the end of life, make hospice an integral part of care for frail patients with MM for whom the risk of standard of care treatment options offsets the benefits. The present study had several limitations. Although the SEEReMedicare-linked database provides a large sample size with diverse demographic data, using claims data and ICD-9 codes for their equivalent CRAB criteria to differentiate SMM versus symptomatic MM has inherent deficiencies. It is possible that the ICD-9 codes were under-or overreported owing to miscoding of the claims data. The possibility also exists of having missed treatments received by patients in our claims analysis. Although the sensitivity and specificity of Medicare claims for MM treatment have not been reported, previous work has shown that Medicare claims were 93% (95% CI, 88%-96%) sensitive for the receipt of parenteral chemotherapy 36 and 47% (95% CI, 32%-62%) sensitive for the receipt of oral chemotherapy. 37 Another limitation of our study was the lack of data on the reason for the receipt of no treatment. We were unable to determine how patient preference, physician recommendations, or other contributing factors influenced the decision not to pursue MM treatment. Patient preference related to the toxicity of treatment might play a significant role. In a study by Postmus et al, 38 treatment benefits (manifested by survival outcomes) and treatment risks (identified as toxicities associated with each treatment) were quantified to help recognize the factors that inform patients' decisions in choosing a certain treatment option for MM. That study revealed that the survival outcomes were of more vital importance than was treatment tolerability when patients select a treatment strategy. 38 However, the SEEReMedicare database does not permit the study of these factors as potential contributors to disparities in treatment. One more limitation of the present study originated from the unavailability of prognostic markers such as staging, cytogenetics, and molecular features in the SEEReMedicare database. Although high-risk cytogenetics and unfavorable mutations, per se, should not justify the lack of treatment, it is possible that some patients with extremely poor prognostic features might elect palliative care alone.
Conclusion
We identified that age, race, comorbidities, poorer performance status indicators, and Medicaid status are associated with receipt of no treatment for MM. These results emphasize the need for a multipronged approach to address outcome disparities in MM. Particular attention to aging-related issues is essential to ensure older and frail patients will benefit from the advances achieved in the field similar to young and healthy patients. Efforts to facilitate clinical trial eligibility for older patients will allow for translation of treatment strategies designed for older frail patients to real-world populations. Approaches focused on improving treatment tolerability might further diminish the outcome disparities in MM by enabling older and more vulnerable older adults to receive effective MM therapy. 39 This multifaceted approach will also require consideration of racial and socioeconomic barriers to access and affordability of therapeutic options that can contribute to the receipt of no treatment. With the growing plethora of treatment options for MM, disease-specific, treatment-specific, and patient-specific characteristics must be considered when selecting an individualized treatment strategy. In the era of novel therapies, it is up to the health care system and health care providers to identify and address any barrier leading to undertreatment and lack of treatment of an individual patient with MM.
Clinical Practice Points
Although advances in MM treatment have improved overall survival, disparities exist in the groups enjoying the benefit of these advances. The known barriers to treatment include age, race, limited health literacy, financial constraints, and professional education gaps, resulting in delayed implementation of advances into community practice.
Our study extracted plasma cell myeloma cases (ICD-O-3 code 9732) in the SEEReMedicare database from 2007 to 2011. Active MM requiring therapy was defined as either claims indicating receipt of treatments approved for MM or ICD-9 codes for MM defining clinical features (CRAB criteria). Multivariate logistic regression was performed to examine the variables independently associated with the receipt of no treatment. Our study found that older age, African-American race, poor performance status indicators, comorbidities, and dual MedicaideMedicare enrollment are independently associated with receipt of no treatment. African-American race and dual MedicaideMedicare enrollment were not associated with the receipt of no novel therapies. Compared with older studies, our results suggest that in the course of time, novel agents have become more accessible to AfricanAmerican patients and patients with low socioeconomic status. Our results highlight the need for a multifaceted approach to address outcome disparities in MM. Particular attention to aging-related issues is essential to ensure older patients will benefit from the advances achieved in the field similar to young patients. Racial and socioeconomic barriers should also be attentively addressed.
With the increasing armamentarium of treatment options for MM, disease-specific, treatment-specific, and patient-specific characteristics should be considered to take the utmost advantage of precision medicine.
